Pretty compelling, and importantly for surgeons, peer reviewed evidence for uptake of Remplir. Not quite the EOFY (Remplir sales) update most OCC holders were hoping for.
That to hopefully follow and that TGA CelGro Tendon (SmrtGraft) approval has not arrived bemuses me.
- Forums
- ASX - By Stock
- OCC
- Ann: Compelling Data Highlights Remplir Competitive Advantage
OCC
orthocell limited
Add to My Watchlist
3.28%
!
$1.26

Ann: Compelling Data Highlights Remplir Competitive Advantage, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.26 |
Change
0.040(3.28%) |
Mkt cap ! $308.4M |
Open | High | Low | Value | Volume |
$1.22 | $1.27 | $1.21 | $737.5K | 596.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6407 | $1.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.26 | 3550 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6407 | 1.230 |
3 | 13641 | 1.225 |
3 | 104178 | 1.220 |
2 | 6139 | 1.215 |
5 | 31061 | 1.210 |
Price($) | Vol. | No. |
---|---|---|
1.260 | 3550 | 1 |
1.265 | 31982 | 2 |
1.270 | 16462 | 2 |
1.275 | 2630 | 1 |
1.280 | 25000 | 2 |
Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |